# Rameen Beroukhim

## List of Publications by Year in Descending Order

| | | | |
|---|---|---|---|
| **133** papers | **25,865** citations | **64** h-index | **147** g-index |
| **147** ext. papers | **33,397** ext. citations | **16.9** avg, IF | **6.11** L-index |

| # | Paper | IF | Citations |
|---|---|---|---|
| 133 | PPM1D mutations are oncogenic drivers of de novo diffuse midline glioma formation.. *Nature Communications*, **2022**, 13, 604 | 17.4 | 0 |
| 132 | DNA-based copy number analysis confirms genomic evolution of PDX models.. *Npj Precision Oncology*, **2022**, 6, 30 | 9.8 | 1 |
| 131 | LGG-58. Understanding the transcriptional heterogeneity of pediatric low-grade gliomas and its implication for tumor pathophysiology. *Neuro-Oncology*, **2022**, 24, i101-i102 | 1 | |
| 130 | RARE-22 Characterizing the landscape of structural variants in adamantinomatous craniopharyngioma. *Neuro-Oncology*, **2022**, 24, i14-i14 | 1 | |
| 129 | LGG-45. Genetic dependencies inMYB/MYBL1-driven pediatric low-grade glioma models. *Neuro-Oncology*, **2022**, 24, i98-i98 | 1 | |
| 128 | Quantification of aneuploidy in targeted sequencing data using ASCETS. *Bioinformatics*, **2021**, 37, 2461-2463 | 7.4 | 4 |
| 127 | Activity of PD-1 blockade with Nivolumab among patients with recurrent atypical/anaplastic meningioma: Phase II trial results. *Neuro-Oncology*, **2021**, | 1 | 7 |
| 126 | TIRR inhibits the 53BP1-p53 complex to alter cell-fate programs. *Molecular Cell*, **2021**, 81, 2583-2595.e6 | 17.6 | 3 |
| 125 | Integrative modeling identifies genetic ancestry-associated molecular correlates in human cancer. *STAR Protocols*, **2021**, 2, 100483 | 1.4 | 0 |
| 124 | Aneuploidy renders cancer cells vulnerable to mitotic checkpoint inhibition. *Nature*, **2021**, 590, 486-491 | 50.4 | 34 |
| 123 | Whole-genome characterization of lung adenocarcinomas lacking the RTK/RAS/RAF pathway. *Cell Reports*, **2021**, 34, 108707 | 10.6 | 7 |
| 122 | Haplotype-resolved germline and somatic alterations in renal medullary carcinomas. *Genome Medicine*, **2021**, 13, 114 | 14.4 | 2 |
| 121 | A Molecularly Integrated Grade for Meningioma. *Neuro-Oncology*, **2021**, | 1 | 7 |
| 120 | Clinical utility of targeted next generation sequencing assay in IDH-wildtype glioblastoma for therapy decision-making. *Neuro-Oncology*, **2021**, | 1 | 3 |
| 119 | MR Imaging Correlates for Molecular and Mutational Analyses in Children with Diffuse Intrinsic Pontine Glioma. *American Journal of Neuroradiology*, **2020**, 41, 874-881 | 4.4 | 10 |
| 118 | Cas9 activates the p53 pathway and selects for p53-inactivating mutations. *Nature Genetics*, **2020**, 52, 662-668 | 36.3 | 69 |
| 117 | Loss of heterozygosity of essential genes represents a widespread class of potential cancer vulnerabilities. *Nature Communications*, **2020**, 11, 2517 | 17.4 | 21 |

| | | | |
|---|---|---|---|
| 116 | Tumor Interferon Signaling Is Regulated by a lncRNA INCR1 Transcribed from the PD-L1 Locus. *Molecular Cell*, **2020**, 78, 1207-1223.e8 | 17.6 | 18 |
| 115 | Treatment-Induced Tumor Dormancy through YAP-Mediated Transcriptional Reprogramming of the Apoptotic Pathway. *Cancer Cell*, **2020**, 37, 104-122.e12 | 24.3 | 107 |
| 114 | Patterns of somatic structural variation in human cancer genomes. *Nature*, **2020**, 578, 112-121 | 50.4 | 232 |
| 113 | Disruption of chromatin folding domains by somatic genomic rearrangements in human cancer. *Nature Genetics*, **2020**, 52, 294-305 | 36.3 | 81 |
| 112 | Early TP53 alterations engage environmental exposures to promote gastric premalignancy in an integrative mouse model. *Nature Genetics*, **2020**, 52, 219-230 | 36.3 | 15 |
| 111 | Targeting Cancer Gene Dependencies with Anthrax-Mediated Delivery of Peptide Nucleic Acids. *ACS Chemical Biology*, **2020**, 15, 1358-1369 | 4.9 | 8 |
| 110 | RARE-07. THE LANDSCAPE OF GENOMIC ALTERATIONS IN ADAMANTINOMATOUS CRANIOPHARYNGIOMAS. *Neuro-Oncology*, **2020**, 22, iii443-iii443 | 1 | 78 |
| 109 | LGG-35. FUNCTIONAL GENOMIC APPROACHES TO IDENTIFY THERAPEUTIC TARGETS IN MYB AND MYBL1 EXPRESSING PEDIATRIC LOW-GRADE GLIOMAS. *Neuro-Oncology*, **2020**, 22, iii373-iii373 | 1 | 78 |
| 108 | HGG-41. STRUCTURAL VARIANT DRIVERS IN PEDIATRIC HIGH-GRADE GLIOMA. *Neuro-Oncology*, **2020**, 22, iii351-iii351 | 1 | 1 |
| 107 | DIPG-53. CHARACTERIZING THE ROLE OF PPM1D MUTATIONS IN THE PATHOGENESIS OF DIFFUSE INTRINSIC PONTINE GLIOMAS (DIPGS). *Neuro-Oncology*, **2020**, 22, iii297-iii297 | 1 | 78 |
| 106 | Comprehensive Analysis of Genetic Ancestry and Its Molecular Correlates in Cancer. *Cancer Cell*, **2020**, 37, 639-654.e6 | 24.3 | 56 |
| 105 | Distinct Classes of Complex Structural Variation Uncovered across Thousands of Cancer Genome Graphs. *Cell*, **2020**, 183, 197-210.e32 | 56.2 | 45 |
| 104 | Histone H3.3G34-Mutant Interneuron Progenitors Co-opt PDGFRA for Gliomagenesis. *Cell*, **2020**, 183, 1617-1633.e22 | 56.2 | 29 |
| 103 | CloneSifter: enrichment of rare clones from heterogeneous cell populations. *BMC Biology*, **2020**, 18, 177 | 7.3 | 3 |
| 102 | Mechanisms and therapeutic implications of hypermutation in gliomas. *Nature*, **2020**, 580, 517-523 | 50.4 | 172 |
| 101 | DIPG-12. CHARACTERIZING THE ROLE OF PPM1D MUTATIONS IN THE PATHOGENESIS OF DIFFUSE INTRINSIC PONTINE GLIOMAS (DIPGs). *Neuro-Oncology*, **2019**, 21, ii70-ii71 | 1 | 78 |
| 100 | Neuronal differentiation and cell-cycle programs mediate response to BET-bromodomain inhibition in MYC-driven medulloblastoma. *Nature Communications*, **2019**, 10, 2400 | 17.4 | 18 |
| 99 | LGG-04. CLINICO-HISTO-MOLECULAR LANDSCAPE OF EIGHTY-TWO PEDIATRIC AND YOUNG ADULT DYSEMBRYOPLASTIC NEUROEPITHELIAL TUMORS. *Neuro-Oncology*, **2019**, 21, ii99-ii99 | 1 | 78 |

| | | | |
|---|---|---|---|
| 98 | Histone demethylase KDM6A directly senses oxygen to control chromatin and cell fate. *Science*, **2019**, 363, 1217-1222 | 33.3 | 165 |
| 97 | Mitogenic and progenitor gene programmes in single pilocytic astrocytoma cells. *Nature Communications*, **2019**, 10, 3731 | 17.4 | 17 |
| 96 | MEDU-36. BCL2 FAMILY MEMBERS ATTENUATE RESPONSE OF MYC-DRIVEN MEDULLOBLASTOMAS TO BET-BROMODOMAIN INHIBITION. *Neuro-Oncology*, **2019**, 21, ii110-ii111 | 1 | 78 |
| 95 | Renal medullary carcinomas depend upon loss and are sensitive to proteasome inhibition. *ELife*, **2019**, 8, | 8.9 | 20 |
| 94 | Longitudinal molecular trajectories of diffuse glioma in adults. *Nature*, **2019**, 576, 112-120 | 50.4 | 151 |
| 93 | miR-4516 predicts poor prognosis and functions as a novel oncogene via targeting PTPN14 in human glioblastoma. *Oncogene*, **2019**, 38, 2923-2936 | 9.2 | 36 |
| 92 | Genomic evolution of cancer models: perils and opportunities. *Nature Reviews Cancer*, **2019**, 19, 97-109 | 31.3 | 104 |
| 91 | Amplification Associates with Aggressive Phenotype but Not Markers of AKT-MTOR Signaling in Endometrial Carcinoma. *Clinical Cancer Research*, **2019**, 25, 334-345 | 12.9 | 9 |
| 90 | Developmental and oncogenic programs in H3K27M gliomas dissected by single-cell RNA-seq. *Science*, **2018**, 360, 331-335 | 33.3 | 255 |
| 89 | Comprehensive Characterization of Cancer Driver Genes and Mutations. *Cell*, **2018**, 173, 371-385.e18 | 56.2 | 854 |
| 88 | Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. *Nature Medicine*, **2018**, 24, 679-690 | 50.5 | 659 |
| 87 | Scalable Open Science Approach for Mutation Calling of Tumor Exomes Using Multiple Genomic Pipelines. *Cell Systems*, **2018**, 6, 271-281.e7 | 10.6 | 320 |
| 86 | Genomic and Functional Approaches to Understanding Cancer Aneuploidy. *Cancer Cell*, **2018**, 33, 676-689.e3 | 24.3 | 377 |
| 85 | Comparative Molecular Analysis of Gastrointestinal Adenocarcinomas. *Cancer Cell*, **2018**, 33, 721-735.e8 | 24.3 | 228 |
| 84 | SvABA: genome-wide detection of structural variants and indels by local assembly. *Genome Research*, **2018**, 28, 581-591 | 9.7 | 149 |
| 83 | Genetic and transcriptional evolution alters cancer cell line drug response. *Nature*, **2018**, 560, 325-330 | 50.4 | 379 |
| 82 | Structural Alterations Driving Castration-Resistant Prostate Cancer Revealed by Linked-Read Genome Sequencing. *Cell*, **2018**, 174, 433-447.e19 | 56.2 | 155 |
| 81 | TMOD-14. A PATIENT-DERIVED CANCER CELL LINE ATLAS OF PRIMARY AND METASTATIC CENTRAL NERVOUS SYSTEM TUMORS. *Neuro-Oncology*, **2018**, 20, vi271-vi271 | 1 | 78 |

| | | | |
|---|---|---|---|
| 80 | PDTM-06. ALK AMPLIFICATION AND REARRANGEMENTS ARE RECURRENT TARGETABLE EVENTS IN GLIOBLASTOMA. *Neuro-Oncology*, **2018**, 20, vi204-vi205 | 1 | 2 |
| 79 | INNV-22. LIQUID BIOPSY DETECTION OF GENOMIC ALTERATIONS IN PEDIATRIC BRAIN TUMORS FROM CELL FREE DNA IN PERIPHERAL BLOOD, CSF, AND URINE. *Neuro-Oncology*, **2018**, 20, vi142-vi143 | 1 | 78 |
| 78 | PATH-16. MOLECULAR PATHOLOGY AND CLINICAL CHARACTERISTICS OF MMR DEFICIENCY (MMRd) IN DIFFUSE GLIOMAS. *Neuro-Oncology*, **2018**, 20, vi161-vi161 | 1 | 78 |
| 77 | DRES-05. MOLECULAR EVOLUTION OF DIFFUSE GLIOMAS AND THE GLIOMA LONGITUDINAL ANALYSIS CONSORTIUM. *Neuro-Oncology*, **2018**, 20, vi76-vi76 | 1 | 78 |
| 76 | Resistance to Epigenetic-Targeted Therapy Engenders Tumor Cell Vulnerabilities Associated with Enhancer Remodeling. *Cancer Cell*, **2018**, 34, 922-938.e7 | 24.3 | 31 |
| 75 | Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition. *Nature Medicine*, **2018**, 24, 968-977 | 50.5 | 126 |
| 74 | Clinical targeted exome-based sequencing in combination with genome-wide copy number profiling: precision medicine analysis of 203 pediatric brain tumors. *Neuro-Oncology*, **2017**, 19, 986-996 | 1 | 39 |
| 73 | Clinical Identification of Oncogenic Drivers and Copy-Number Alterations in Pituitary Tumors. *Endocrinology*, **2017**, 158, 2284-2291 | 4.8 | 42 |
| 72 | MicroRNA Signatures and Molecular Subtypes of Glioblastoma: The Role of Extracellular Transfer. *Stem Cell Reports*, **2017**, 8, 1497-1505 | 8 | 49 |
| 71 | Genomic landscape of high-grade meningiomas. *Npj Genomic Medicine*, **2017**, 2, | 6.2 | 78 |
| 70 | Leveraging molecular datasets for biomarker-based clinical trial design in glioblastoma. *Neuro-Oncology*, **2017**, 19, 908-917 | 1 | 14 |
| 69 | Pan-Cancer Analysis Links PARK2 to BCL-XL-Dependent Control of Apoptosis. *Neoplasia*, **2017**, 19, 75-83 | 6.4 | 23 |
| 68 | Patient-derived xenografts undergo mouse-specific tumor evolution. *Nature Genetics*, **2017**, 49, 1567-1575 | 36.3 | 384 |
| 67 | Somatic copy number alterations in gastric adenocarcinomas among Asian and Western patients. *PLoS ONE*, **2017**, 12, e0176045 | 3.7 | 22 |
| 66 | Genomic profile of human meningioma cell lines. *PLoS ONE*, **2017**, 12, e0178322 | 3.7 | 30 |
| 65 | Germline and somatic BAP1 mutations in high-grade rhabdoid meningiomas. *Neuro-Oncology*, **2017**, 19, 535-545 | 1 | 60 |
| 64 | Landscape of Genomic Alterations in Pituitary Adenomas. *Clinical Cancer Research*, **2017**, 23, 1841-1851 | 12.9 | 64 |
| 63 | Tyrosine receptor kinase B is a drug target in astrocytomas. *Neuro-Oncology*, **2017**, 19, 22-30 | 1 | 26 |

| | | | |
|---|---|---|---|
| 62 | Radiographic prediction of meningioma grade by semantic and radiomic features. *PLoS ONE*, **2017**, 12, e0187908 | 3.7 | 66 |
| 61 | Copy-number and gene dependency analysis reveals partial copy loss of wild-type SF3B1 as a novel cancer vulnerability. *ELife*, **2017**, 6, | 8.9 | 49 |
| 60 | SeqLib: a C ++ API for rapid BAM manipulation, sequence alignment and sequence assembly. *Bioinformatics*, **2017**, 33, 751-753 | 7.2 | 5 |
| 59 | Myxopapillary ependymomas in children: imaging, treatment and outcomes. *Journal of Neuro-Oncology*, **2016**, 126, 165-174 | 4.8 | 28 |
| 58 | Copy number alterations unmasked as enhancer hijackers. *Nature Genetics*, **2016**, 49, 5-6 | 36.3 | 25 |
| 57 | Recurrent hormone-binding domain truncated ESR1 amplifications in primary endometrial cancers suggest their implication in hormone independent growth. *Scientific Reports*, **2016**, 6, 25521 | 4.9 | 11 |
| 56 | The genomic landscape and evolution of endometrial carcinoma progression and abdominopelvic metastasis. *Nature Genetics*, **2016**, 48, 848-55 | 36.3 | 135 |
| 55 | Genomic landscape of intracranial meningiomas. *Journal of Neurosurgery*, **2016**, 125, 525-35 | 3.2 | 62 |
| 54 | CANCER. The oncogene makes its escape. *Science*, **2016**, 351, 1398-9 | 33.3 | 2 |
| 53 | Genomic and Epigenomic Landscape in Meningioma. *Neurosurgery Clinics of North America*, **2016**, 27, 167-79 | 4 | 24 |
| 52 | Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma. *Cell*, **2016**, 164, 550-63 | 56.2 | 1140 |
| 51 | MYB-QKI rearrangements in angiocentric glioma drive tumorigenicity through a tripartite mechanism. *Nature Genetics*, **2016**, 48, 273-82 | 36.3 | 154 |
| 50 | Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma. *Neuro-Oncology*, **2016**, 18, 649-55 | 1 | 144 |
| 49 | VariantBam: filtering and profiling of next-generational sequencing data using region-specific rules. *Bioinformatics*, **2016**, 32, 2029-31 | 7.2 | 14 |
| 48 | MECP2 Is a Frequently Amplified Oncogene with a Novel Epigenetic Mechanism That Mimics the Role of Activated RAS in Malignancy. *Cancer Discovery*, **2016**, 6, 45-58 | 24.4 | 35 |
| 47 | MAPK activation and HRAS mutation identified in pituitary spindle cell oncocytoma. *Oncotarget*, **2016**, 7, 37054-37063 | 3.3 | 24 |
| 46 | Case Report: Next generation sequencing identifies a NAB2-STAT6 fusion in Glioblastoma. *Diagnostic Pathology*, **2016**, 11, 13 | 3 | 8 |
| 45 | Disseminated glioneuronal tumors occurring in childhood: treatment outcomes and BRAF alterations including V600E mutation. *Journal of Neuro-Oncology*, **2016**, 128, 293-302 | 4.8 | 36 |

| | | | |
|---|---|---|---|
| 44 | The genomic landscape of schwannoma. *Nature Genetics*, **2016**, 48, 1339-1348 | 36.3 | 74 |
| 43 | Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. *New England Journal of Medicine*, **2015**, 372, 2481-98 | 59.2 | 1828 |
| 42 | ARID1A and TERT promoter mutations in dedifferentiated meningioma. *Cancer Genetics*, **2015**, 208, 345-50 | 2.9 | 57 |
| 41 | Predicting clinical response to anticancer drugs using an ex vivo platform that captures tumour heterogeneity. *Nature Communications*, **2015**, 6, 6169 | 17.4 | 185 |
| 40 | Clinical implementation of integrated whole-genome copy number and mutation profiling for glioblastoma. *Neuro-Oncology*, **2015**, 17, 1344-55 | 1 | 39 |
| 39 | Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. *Cancer Discovery*, **2015**, 5, 1164-1177 | 24.4 | 581 |
| 38 | Structure and mechanism of activity-based inhibition of the EGF receptor by Mig6. *Nature Structural and Molecular Biology*, **2015**, 22, 703-711 | 17.6 | 56 |
| 37 | Extent of resection and overall survival for patients with atypical and malignant meningioma. *Cancer*, **2015**, 121, 4376-81 | 6.4 | 105 |
| 36 | Expression profiles of 151 pediatric low-grade gliomas reveal molecular differences associated with location and histological subtype. *Neuro-Oncology*, **2015**, 17, 1486-96 | 1 | 33 |
| 35 | Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma. *Neuro-Oncology*, **2015**, 17, 862-7 | 1 | 84 |
| 34 | An in-tumor genetic screen reveals that the BET bromodomain protein, BRD4, is a potential therapeutic target in ovarian carcinoma. *Proceedings of the National Academy of Sciences of the United States of America*, **2015**, 112, 232-7 | 11.5 | 112 |
| 33 | Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma. *Neurology*, **2015**, 84, 280-6 | 6.5 | 62 |
| 32 | Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition. *Cancer Cell*, **2014**, 25, 393-405 | 24.3 | 469 |
| 31 | Pan-cancer genetic analysis identifies PARK2 as a master regulator of G1/S cyclins. *Nature Genetics*, **2014**, 46, 588-94 | 36.3 | 124 |
| 30 | Long-term outcome of 4,040 children diagnosed with pediatric low-grade gliomas: an analysis of the Surveillance Epidemiology and End Results (SEER) database. *Pediatric Blood and Cancer*, **2014**, 61, 1173-9 | 3 | 158 |
| 29 | Pediatric low-grade gliomas: how modern biology reshapes the clinical field. *Biochimica Et Biophysica Acta: Reviews on Cancer*, **2014**, 1845, 294-307 | 11.2 | 28 |
| 28 | BET bromodomain inhibition of MYC-amplified medulloblastoma. *Clinical Cancer Research*, **2014**, 20, 912-25 | 12.9 | 227 |
| 27 | SGK3 mediates INPP4B-dependent PI3K signaling in breast cancer. *Molecular Cell*, **2014**, 56, 595-607 | 17.6 | 105 |

| | | | |
|---|---|---|---|
| 26 | Retrospective study of carmustine or lomustine with bevacizumab in recurrent glioblastoma patients who have failed prior bevacizumab. *Neuro-Oncology*, **2014**, 16, 1523-9 | 1 | 19 |
| 25 | Epigenetic targeting of Hedgehog pathway transcriptional output through BET bromodomain inhibition. *Nature Medicine*, **2014**, 20, 732-40 | 50.5 | 213 |
| 24 | Adjuvant radiation therapy, local recurrence, and the need for salvage therapy in atypical meningioma. *Neuro-Oncology*, **2014**, 16, 1547-53 | 1 | 61 |
| 23 | Tumor associated seizures in glioblastomas are influenced by survival gene expression in a region-specific manner: a gene expression imaging study. *Epilepsy Research*, **2014**, 108, 843-52 | 3 | 13 |
| 22 | AT-36PANOBINOSTAT IN COMBINATION WITH BEVACIZUMAB FOR RECURRENT GLIOBLASTOMA AND ANAPLASTIC GLIOMA. *Neuro-Oncology*, **2014**, 16, v16-v16 | 1 | 78 |
| 21 | Angiomatous meningiomas have a distinct genetic profile with multiple chromosomal polysomies including polysomy of chromosome 5. *Oncotarget*, **2014**, 5, 10596-606 | 3.3 | 46 |
| 20 | Systematic screening reveals a role for BRCA1 in the response to transcription-associated DNA damage. *Genes and Development*, **2014**, 28, 1957-75 | 12.6 | 66 |
| 19 | Clinical multiplexed exome sequencing distinguishes adult oligodendroglial neoplasms from astrocytic and mixed lineage gliomas. *Oncotarget*, **2014**, 5, 8083-92 | 3.3 | 46 |
| 18 | The somatic genomic landscape of glioblastoma. *Cell*, **2013**, 155, 462-77 | 56.2 | 2900 |
| 17 | Pan-cancer patterns of somatic copy number alteration. *Nature Genetics*, **2013**, 45, 1134-40 | 36.3 | 1198 |
| 16 | SQSTM1 is a pathogenic target of 5q copy number gains in kidney cancer. *Cancer Cell*, **2013**, 24, 738-50 | 24.3 | 111 |
| 15 | Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity. *Nature Genetics*, **2013**, 45, 478-86 | 36.3 | 558 |
| 14 | Somatic rearrangements across cancer reveal classes of samples with distinct patterns of DNA breakage and rearrangement-induced hypermutability. *Genome Research*, **2013**, 23, 228-35 | 9.7 | 109 |
| 13 | Cancer vulnerabilities unveiled by genomic loss. *Cell*, **2012**, 150, 842-54 | 56.2 | 163 |
| 12 | Absolute quantification of somatic DNA alterations in human cancer. *Nature Biotechnology*, **2012**, 30, 413-21 | 44.5 | 1229 |
| 11 | Chemical genomics identifies small-molecule MCL1 repressors and BCL-xL as a predictor of MCL1 dependency. *Cancer Cell*, **2012**, 21, 547-62 | 24.3 | 145 |
| 10 | GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. *Genome Biology*, **2011**, 12, R41 | 18.3 | 1614 |
| 9 | The landscape of somatic copy-number alteration across human cancers. *Nature*, **2010**, 463, 899-905 | 50.4 | 2590 |

# List of Publications

| 8 | Patterns of gene expression and copy-number alterations in von-hippel lindau disease-associated and sporadic clear cell carcinoma of the kidney. *Cancer Research*, **2009**, 69, 4674-81 | 10.1 | 327 |
|---|---|---|---|
| 7 | Highly parallel identification of essential genes in cancer cells. *Proceedings of the National Academy of Sciences of the United States of America*, **2008**, 105, 20380-5 | 11.5 | 424 |
| 6 | Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. *Proceedings of the National Academy of Sciences of the United States of America*, **2007**, 104, 20007-12 | 11.5 | 812 |
| 5 | Inferring loss-of-heterozygosity from unpaired tumors using high-density oligonucleotide SNP arrays. *PLoS Computational Biology*, **2006**, 2, e41 | 5 | 124 |
| 4 | SvABA: Genome-wide detection of structural variants and indels by local assembly | | 5 |
| 3 | Selective and mechanistic sources of recurrent rearrangements across the cancer genome | | 20 |
| 2 | The Tangent copy-number inference pipeline for cancer genome analyses | | 3 |
| 1 | Novel patterns of complex structural variation revealed across thousands of cancer genome graphs | | 8 |